{"nctId":"NCT00853827","briefTitle":"Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients","startDateStruct":{"date":"2009-03"},"conditions":["Coronary Artery Disease (CAD)","Coronary Atherosclerosis"],"count":613,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Aliskiren","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with CAD who have blood pressure in the pre-hypertensive range defined as a msSBP ≥ 125 and ≤ 139mmHg and a msDBP \\< 90mmHg.\n* Patients with or without current treatment for hypertension\n* Angiographic evidence of coronary artery disease\n* At least 2 qualifying Cardiovascular risk factors at Visit 1\n\nExclusion Criteria:\n\n* Baseline IVUS determined unacceptable\n* Patients requiring treatment with disallowed study medications\n* Patients with clinically significant heart disease\n* Previous or current diagnosis of heart failure (NYHA Class IV) or a documented left ventricular ejection fraction of \\< 25%\n* Patients requiring treatment with any 2 of the following classes of medication at Visit 1 or Visit 2:\n\n  * Angiotensin converting enzyme inhibitors\n  * Angiotensin receptor blockers\n  * aldosterone receptor blockers or a direct renin inhibitor.\n* Other conditions may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment","description":"Change from baseline in PAV for all matched slices of anatomically comparable segments of the target coronary artery were assessed by intravascular ultrasound (IVUS) evaluation after 104 weeks of treatment . calculation for change is the value at the later time point minus the value at the earlier time point, with positive numbers to represent increases and negative numbers to represent decreases","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.18"},{"groupId":"OG001","value":"0.11","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change in Normalized Total Atheroma Volume (TAV) as Assessed by IVUS","description":"Change from baseline in normalized total atheroma volume (TAV) (mm\\^3) for all matched slices of anatomically comparable segments of the target coronary artery were assess by IVUS after 104 weeks of treatment. calculation for change is the value at the later time point minus the value at the earlier time point, with positive numbers to represent increases and negative numbers to represent decreases","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.11","spread":"1.10"},{"groupId":"OG001","value":"-2.07","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Patients That Demonstrated Evidence of Atheroma Regression","description":"Atheroma regression is defined as change from baseline to endpoint in PAV \\<0 .","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events, Serious Adverse Events, and Death","description":"overall safety and tolerability of aliskiren 300 mg compared to placebo in patients with CAD and BP in the pre-hypertensive (high normal) range with or without treatment for hypertension following 104 weeks of treatment. Any Adverse Event was defined as occurrence of any symptom regardless of intensity grade, Serious Adverse Event (SAEs) assessed as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in persistent or significant disability/incapacity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"228","spread":null},{"groupId":"OG001","value":"227","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":76,"n":305},"commonTop":["Dizziness","Fatigue","Angina pectoris","Non-cardiac chest pain","Headache"]}}}